Maryland Board Approves Drug Payment Caps Projected to Save $6.1M a Year

By Finks Desk
Maryland Board Approves Drug Payment Caps Projected to Save $6.1M a Year

Drugmakers now face a US state that pays what Medicare negotiated, not what the manufacturer asks. Maryland's Prescription Drug Affordability Board gave final approval Monday, Nov. 16, to payment caps on two high-cost drugs for state and local government health plans, the first such limits by a state on either drug.

Novo Nordisk sells Ozempic at a list price of about $1K a month. Maryland's limit is $274 per 30-day supply. Novo Nordisk plans to cut Ozempic's list price to $675 a month on Jan. 1, the same date the caps can begin.

Jardiance, marketed by Eli Lilly and Boehringer Ingelheim, works the same way: its Medicare price is $197 a month, and Maryland's $204 ceiling is that price adjusted for inflation.

Neither number came from a negotiation with the manufacturer. The $274 figure is exactly the Medicare maximum fair price for semaglutide taking effect in 2027, and the board's staff calculation adopts it without adjustment.

Maryland Set Its Caps at Medicare's Prices

Monthly Medicare maximum fair price vs Maryland upper payment limit, per 30-day supply, US dollars, 2027

  • Medicare maximum fair price
  • Maryland upper payment limit

Bar chart. Monthly price ($). Ozempic: Medicare maximum fair price $274, Maryland upper payment limit $274. Jardiance: Medicare maximum fair price $197, Maryland upper payment limit $204.

Source: Maryland Prescription Drug Affordability Board staff calculation (payment limits), CMS maximum fair prices, as reported by Peptide News Digest (Medicare benchmark)

What the caps touch

The limits bind what government plans reimburse, not what a company lists and not what a patient hands over at the pharmacy counter.

Medicaid, 340B purchases, and self-insured Medicare retiree plans sit outside the rules, along with private employer and marketplace plans, per the board's implementation rules.

Eligible government entities can adopt the caps voluntarily from Jan. 1, 2027, and participating entities must apply them after Jan. 1, 2028.

Board staff project roughly $6.1M a year in savings for state and local governments.

The board describes an upper payment limit as the maximum amount eligible entities will reimburse for a given drug.

"Now, the state is saying, you could charge whatever you want, but we are only going to pay a reasonable amount here in Maryland."

Vinny DeMarco, Maryland Healthcare for All coalition

The 2028 expansion is the bigger number

Putting the limits into effect starts the clock on extending the board's authority to Maryland's private insurance market in 2028.

Annual savings could top $150M once the caps reach commercial plans, a step change from the government-plan figure.

Gov. Wes Moore and several lawmakers back legislation letting the board set limits on any drug with a Medicare negotiated price. There are 25 such drugs already.

The legal path is unsettled. Colorado's board set the country's first limit, on Amgen's Enbrel, and a federal judge blocked it with a preliminary injunction in July, ruling that federal patent law preempts caps on patented drug prices.

Colorado also tied its number to Medicare's price, which puts the same reasoning in front of Maryland's approach.

Patient advocacy groups and manufacturers warn the caps could reshuffle formularies or push pharmacies to stop stocking the drugs, and the board says it may revise the policy if access suffers.

For Novo Nordisk and Lilly, the precedent is that a state can set its payment rate off a federal benchmark without sitting at the table. The GLP-1 boom that made both drugs budget lines has a longer arc.